Document 61173

Michael Camilleri, MD, PhD*
Functional gastrointestinal (GI) disorders are collections of symptoms attributable to the GI tract in
the absence of mucosal, structural, or biochemical
disease. Two of the most common disorders, chronic constipation and irritable bowel syndrome (IBS),
have common etiopathogenetic features—notably
psychosocial disturbances, dysmotility, and heightened sensitivity. In some patients with IBS, there is an
association with a postinfective state. In constipation,
transit disorders and abnormal evacuation represent disturbances of function that are amenable to
therapy. This review is an update of the mechanisms
and pathophysiology of these disorders. IBS and
constipation are defined, and control of gut motility
and sensation and their disturbances in these disorders are reviewed along with the mechanisms and
pathophysiology of IBS and constipation.
(Adv Stud Med. 2005;5(10B):S955-S964)
unctional gastrointestinal (GI) disorders
are defined as collections of functional
symptoms that are not attributable to
structural, mucosal, or biochemical diseases of the GI tract.1 Symptoms include
indigestion, abdominal pain, bloating, distension, and
symptoms of disordered defecation. The most common functional bowel disorders are functional dyspepsia, irritable bowel syndrome (IBS), and chronic
*Atherton and Winifred W. Bean Professor, Professor of
Medicine and Physiology, Mayo Clinic College of
Medicine; Consultant in Gastroenterology, Mayo Clinic,
Rochester, Minnesota.
Address correspondence to: Michael Camilleri, MD, PhD,
Mayo Clinic, Charlton 8-110, 200 First St SW, Rochester,
MN 55905. E-mail: [email protected]
Advanced Studies in Medicine
constipation.2,3 These are biopsychosocial disorders in
which psychosocial factors, prior gastroenteritis,
abnormal motility, gas retention, and heightened sensation interact to induce symptoms.
IBS is the most common functional bowel disorder
and is characterized by chronic or recurrent symptoms
that are thought to arise in the small bowel or colon.
Symptoms have been embodied in the Manning4 or
Rome II1,2 criteria and include lower abdominal pain
related to bowel movements, changing bowel habit
(eg, diarrhea, constipation, or alternating between the
two), abdominal bloating, a sense of incomplete rectal
evacuation, and passage of mucus.
Constipation is variably defined, but usually refers to
persistent difficult, infrequent, or seemingly incomplete
defecation.5 Diagnosis often is arbitrary and may depend
on the patient’s perception of what is abnormal. The
prevalence of constipation depends on the definition and
the population studied. Individual patients’ symptoms
must be analyzed in detail to ascertain what is meant by
“constipation” or “difficulty” with defecation (Figure 1).
Patients also may perceive incorrectly that they are constipated. When formally evaluated via daily diary during
a 4-week period, only 20 out of 44 patients who perceived they were constipated had reduced stool frequency
(ie, <3 bowel movements per week).6 The perception of
hard stools or excessive straining is more difficult to assess
objectively, though instruments such as the Bristol Stool
Form Scale7 may be helpful. The need for enemas or digital disimpaction is a clinically useful marker to corroborate the patient’s perceptions of difficult defecation.
In addition to classical concepts of the pathophysiology of IBS,8 this section addresses current understanding9
of the role of inflammation in IBS and the potential of
novel mechanisms, serotonin, genetics, and intraluminal
factors. Intrinsic and extrinsic neural influences modulate
the motor and sensory functions of the gut (Figure 2).
The pivotal mechanisms involved in the pathophysiology of IBS are altered psychosocial function,
motility, and hypersensitivity. Psychosocial aspects8 are
important determinants of the emotional response to
visceral stimulation, and they influence the time to
presentation as well as the severity of disease—and
provide the rationale for treatment with antidepressants and other behavioral approaches.
Important motor dysfunctions10 include prominent
symptoms and colonic contractions after feeding in diarrhea-predominant IBS (D-IBS),11,12 and poor colonic
response in constipation-predominant IBS (C-IBS) or
functional constipation associated with slow transit.13
Disturbances of transit profiles reflect the predominant
bowel dysfunction,14-16 and gas transit also is demonstrable experimentally and is related to bloating sensation.17,18
An associated evacuation disorder (eg, puborectalis
spasm) may result in an overlap with symptoms of CIBS.19,20 Epidemiologic studies document overlap with
upper functional disease, specifically dyspepsia or upper
abdominal pain, which occurred in 80% of IBS patients
in one study.21
Overlap of IBS with celiac disease may merely
reflect the concurrence of 2 relatively common disorders in the same person and the limited repertoire of
symptoms of diverse gut disorders. Screening for celiac disease is important in susceptible populations;
however, population-based studies in a community
with a predominant northern European extraction
suggest that serologic screening does not identify significant numbers of patients with celiac disease among
individuals with IBS and dyspepsia.22
Visceral hypersensitivity and hyperalgesia are well
documented in IBS,23-28 and the rectal sensory threshold for pain of 32 mm Hg has relatively high sensitivity and specificity for identifying hypersensitivity. The
increased activation of the limbic or emotional motor
system in IBS patients during rectal distension has
been confirmed in several studies.29,30
Figure 1. Mechanisms Involved in Continence and
Defecation in Humans*
At Rest
During Straining
External anal
Internal anal
Descent of the pelvic floor
The figure shows a sagittal section through the pelvis and emphasizes the role of the
pubo-rectalis and pelvic floor muscles in facilitating continence by contraction and
allowing defecation by the straightening of the anorectal angle. Conversely, pelvic
floor dyssynergia may result in obstruction to defecation with a sense of incomplete
evacuation, constipation, and secondary abdominal discomfort.
*Reprinted with permission from Lembo A, Camilleri M. Chronic constipation. N Engl
J Med. 2003;349:1360-1368.20 Copyright © 2003. Massachusetts Medical Society. All
rights reserved.
Figure 2. Extrinsic and Intrinsic Control of Gut Motility
Parasym pathetic
IC C s
Enteric brain
10 8 neurons
smooth muscle cell
with receptors for transmitters
modulates peristaltic reflex
IPAN: sensory
V IP /
AC h
S u b P /S u b K
Ascending contraction Descending relaxation
d is t e n ti o n b y b o l u s
Several lines of evidence address this question.
First, epidemiologic studies suggest an association
between inflammation as a result of earlier infection and
The enteric nervous system controls stereotypic motor functions such as the migrating motor complex and the peristaltic reflex; intrinsic control is modulated by the
extrinsic parasympathetic and sympathetic nerves, which respectively stimulate and
inhibit nonsphincteric muscle.
ICC = interstitial cells of Cajal; IPAN = intrinsic primary afferent neuron.
Vol. 5 (10B)
November 2005
the persistence of IBS symptoms.8 The interdependence
of prior infection and psychologic status also has been
consistently documented,8 and may raise questions as to
the role of persistent inflammation as an independent
risk factor. Alternatively, the data are interpreted as evidence of the importance of psychoneuroimmune interactions; it is unclear whether inflammation is a common
final pathway to nonspecific psychologic influence on
gut function and the prior infection potentially unrelated, other than as an initiator of the cascade of events.
However, a summary of the epidemiology data also
shows that the prevalence of postinfectious IBS (PI-IBS)
is no higher than IBS in the general population.
In addition, several studies have documented
increased numbers of CD3, CD25, or mast cells in
ileal, colonic, or rectal biopsy specimens,31-38 but the
differences in lymphocyte counts between controls
and IBS are small, with predominant overlap in the
counts between the 2 conditions. A few outliers seem
to be exceptions, and it is unclear whether these higher immune cell counts have functional significance (eg,
influence sensitivity or permeability).
Differences in ileal mast cell numbers34-38 between
IBS and controls appear to be more substantial and consistent, and there is now evidence of functional correlates
in the significant association between mast cells in close
proximity to nerves and severity and frequency of
abdominal pain.38 Nevertheless, it is significant that only
1 of 5 markers of mast cell morphology was associated
with IBS, sample size was small, and the correlation is
influenced by the fact that 3 out of 13 patients with IBS
had no pain (which, based on current criteria, raises the
question of whether they indeed had IBS).
The third line of evidence to be examined is the
response of IBS to anti-inflammatory treatment. A
controlled trial has shown that, among carefully selected patients with PI-IBS, a 30-mg dose of prednisone
taken twice daily was not significantly better than
placebo and that, whereas placebo resulted in the customary significant 30% change in median symptom
score relative to baseline, no change in score was noted
in the prednisone treatment group.39 Controlled studies with other anti-inflammatory agents are needed.
Some have suggested that IBS is a disorder of sero-
Advanced Studies in Medicine
tonin, quoting recent evidence that modulation of
serotonergic mechanisms significantly impacts the
manifestations of IBS. In some respects, this is a borrowed concept, as serotonin is a key player in the secretion and dysmotility of the carcinoid syndrome,40 in
which 5-hydroxytryptamine3 (5-HT3) antagonists
reduce the colonic response to feeding,41 diarrhea, and
the need for rescue antidiarrheal agents.42
There are other more direct lines of evidence to
address the potential role of serotonin. First, plasma 5HT levels are elevated in patients with IBS.43,44 Postmeal symptoms can be prominent in IBS patients,45
and Houghton et al attempted to correlate postprandial symptoms and increased plasma 5-HT.44 However,
it appears that the peak in plasma 5-HT levels does not
coincide with the time (60 to 90 minutes after a meal)
at which patients with IBS typically experience pain,
diarrhea, and urgency.46
Second, enteroendocrine cells in rectal biopsies of
PI-IBS patients show significantly increased numbers
of 5-HT–containing cells. These quantitative differences were more impressive in one study31 than in a
subsequent study from Spiller’s group32; and overlap
with numbers in disease control groups or non–PI-IBS
suggests that prior infection may not be a key factor.
A third line of study assessed factors involved in the
control of 5-HT in IBS via examination of mucosal
biopsy specimens from patients with IBS, healthy
patients without IBS, and disease controls (who had
ulcerative colitis). Coates et al47 showed that the number of enteroendocrine E cells containing 5-HT was
normal, in contrast to other studies,31,32 and the release
of 5-HT from mucosal biopsy specimens under baseline conditions or in response to stimulation was normal.47 However, the mucosal content of the 5-HT
reuptake protein, serotonin transporter (SERT), was
reduced, as shown by SERT messenger RNA content
and immunohistochemistry.47 These changes paralleled
the findings in nonsevere ulcerative colitis, and it is
unlikely that the diarrhea itself induced the changes,
because results were similar in D-IBS and C-IBS. The
mechanisms causing these changes and their functional importance remain the subject of continued
research. Certainly, differences in SERT function
appear to influence the response to therapy in IBS,48
and further studies are forthcoming.
Fourth, serotonergic agents, including 5-HT3
antagonists49 and 5-HT4 agonists,50 are effective in the
treatment of multiple symptoms of IBS.
Three lines of evidence suggest there may be a role for
genetics in IBS, but the data are inconclusive at present.
First, familial aggregation studies suggest that family members of individuals with IBS are more likely to
suffer from IBS than are their spouse controls.51,52
Second, twin studies also document a difference
between risk of IBS in monozygotic twins compared
with dizygotic twins53,54; however, the fact that mothers
of mono- and dizygotic twins have similar prevalence of
IBS suggests that heredity and social learning or other
environmental factors interact as risk factors in development of IBS. One study from the United Kingdom did
not confirm increased IBS prevalence in twins.55
Third, genetic epidemiology studies provide some
evidence of a genetic association in IBS. However,
these data are to be viewed as preliminary and the pitfalls of such association studies, which may be underpowered, should be kept in mind.
Fewer IBS patients have high interleukin (IL)-10
producer (G/G) genotype than do controls.56 Reduced
IL-10 production in these patients may lead to an
inability to down-regulate inflammation, which may
be a factor in the development of IBS.
Holtmann et al have shown that a polymorphism
in the gene for the G protein involved in mediating
the effects of several neurotransmitters and hormones,
G-protein ß subunit gene (GNß3 C825T) genotype,
is significantly associated with the report of dyspepsia
and, to a lesser extent, IBS in patients presenting to a
clinic in Germany.57
Adrenergic and serotonergic genotypes were investigated in 276 IBS patients and 120 community controls.
A 44-base pair deletion in the gene for the promoter for
SERT (SERT-P) previously has been shown to influence
the function of the SERT protein produced.58 Thus, the
wild-type L/L polymorphism results in normal function,
whereas the presence of the short allele (S/L or S/S)
results in impaired function.58 Kim et al59 showed in 90
C-IBS patients a significant association with α2A
adrenoceptor polymorphism, and the combination of
the α2 adrenoceptor and SERT-P polymorphism was
associated with high somatic scores in patients with
lower functional GI disorders (FGIDs). SERT-P alone
was not a risk factor for D-IBS in the Mayo Clinic
study,59 and a summary of studies to date60 suggests there
is no significant association with IBS or its subtypes in
studies from North America and Korea.61,62 A positive
association with D-IBS in Turkey63 should be viewed
with caution, given the ethnic differences in the genetic
distribution of the polymorphism and the small sample
studied (n=18). In summary, the reduced mucosal SERT
in C-IBS and D-IBS observed by Coates et al47 does not
appear to be genetically determined, based on reports in
the literature to date.
Changes in the intraluminal milieu may result in
symptoms that may be alleviated by treatments directed at the intraluminal factors.
Symptom overlap exists between idiopathic bile acid
catharsis and rapid ideal transit that results in failure of
bile acid absorption. Bile salt retention is reduced in
patients who have functional diarrhea with or without
associated pain.64 Patients with IBS show higher intestinal
secretion in response to perfused bile acids in the ileum,
compared with controls.65 Retarding transit with loperamide reduces the risk of bile salt loss.66 It therefore is
not surprising that bile salt binding with cholestyramine
may be effective in the treatment of IBS with diarrhea.
Perfusion of the mammalian or human colon with
di-α-hydroxy bile acids such as chenodeoxycholic acid
or short-chain fatty acids results in high-amplitude
propagated contractions or rapid transit in a healthy
colon.67-70 Studies have not been conducted in IBS
patients. However, the relatively low concentrations of
bile acid (1 mmol/L) required to induce highly
propulsive propagated sequences71 suggest that relatively modest levels of malabsorption may be sufficient
to perturb colonic motility. The concentrations of longchain fatty acids (eg, oleic acid) required to accelerate
colon transit are relatively high, but certainly would be
in the range associated with moderate fat malabsorption.67 Such colonic concentrations of longer-chain
fatty acids are unlikely to be achieved in patients with
IBS, although formal studies with long- and shortchain fatty acids are required.
Small studies suggest that probiotics or antibiotics
aimed at changing bacterial counts may indeed alter
symptoms, although the mechanism is still unclear.
Nobaek et al showed that alteration of intestinal
microflora via probiotics was associated with reduction
in abdominal bloating and pain in patients with IBS.72
Vol. 5 (10B)
November 2005
Similarly, Kim et al showed that, in patients with IBS, the
combination probiotic, VSL#3, resulted in improvement
of the symptoms of bloating and flatulence in 2 separate
studies, but there was no other symptom or global relief.73
In the second study, there was a slight, but significant
retardation of colonic transit without significant alteration of bowel function.74 Quigley et al have preliminarily reported a benefit with Bifidobacteria- but not with
Lactobacillus-containing probiotics.75 This benefit was
associated with restoration of normal IL-10/IL-12 ratios
in plasma, suggesting that the probiotic normalized
immune function in these patients.75
Finally, change in the bacterial ecology with the nonabsorbable antibiotic, neomycin, results in short-term
improvement in the composite score for IBS and bowel
dysfunction.76 These effects were observed in a 7-day trial.
Interestingly, patients whose lactulose-hydrogen breath
test normalized had greater improvement than those with
no response in breath hydrogen. The author’s interpretation is that this represents an effect on bacterial overgrowth in the small bowel in IBS. Whereas this
interpretation may be questioned and longer-term studies and outcomes of treatment with bacterial modification need to be evaluated, the role of the intestinal milieu
and the effects of bacteria and endogenous factors such as
bile acids and fatty acids in the mechanisms and treatment of IBS deserve further study.
Although there is increasing evidence that IBS represents an enteric neurologic disorder that alters bowel sensation, secretion, and motility, it is important to
continue to study inflammation and the potential for
intraluminal factors resulting in dysregulation of those
functions. Central mechanisms may enhance visceral
sensation or the interpretation of ascending visceral signals as unpleasant because of the disturbances in the limbic system, which is involved in the affective response to
pain. At this time, the role of genetics is uncertain. These
data suggest that therapies should continue to be directed at these pathophysiologic mechanisms in the gut and
central control. However, it is conceivable that further
understanding of the bowel ecology in health and disease
may open new avenues for treatment of IBS.
Constipation is a common symptom affecting
between 2%77,78 and 27%79 of the population in Western
countries and between 10% and 15% in the United
States.80 In the United States, it results in more than 2.5
Advanced Studies in Medicine
million visits to physicians, 92 000 hospitalizations,78
and laxative sales of several hundred million dollars a
year. Constipation is more prevalent in women than in
men,7 in nonwhite than in white persons,5 in children
than in adults,6 and in older than in younger adults.81-84
Severe constipation (eg, bowel movements only twice a
month) is seen almost exclusively in women.7 Physical
inactivity, low income, limited education, a history of
sexual abuse, and symptoms of depression all are risk
factors for constipation.81
There is no single definition of constipation. Most
patients define constipation as having 1 or more of the
following symptoms: hard stools, infrequent stools
(typically fewer than 3 per week), the need for excessive straining upon defecation, a sense of incomplete
bowel evacuation, and excessive time spent on the toilet or in unsuccessful defecation.83,84 An epidemiologic
study of constipation in the United States identified
the condition as an inability to evacuate stool completely and spontaneously 3 or more times per week.77
A consensus definition of constipation (the Rome II
criteria) used in current research is provided in Table 1.3
Constipation frequently is multifactorial and can
result from systemic or neurologic disorders or medications. Constipation can be classified into 3 broad
categories: normal-transit constipation, slow-transit
constipation, and disorders of defecatory or rectal
evacuation. More than 1 mechanism may contribute
to constipation. In a study of more than 1000 patients
with chronic constipation (CC),85 normal transit
through the colon was the most prevalent form (occurring in 59% of patients), followed by defecatory disorders (25%), slow transit (13%), and a combination of
defecatory disorders and slow transit (3%).
Normal-transit constipation (or “functional” constipation) is the most common form of constipation that
clinicians see. In patients with this disorder, stool traverses at a normal rate through the colon and the stool
frequency is normal, yet patients believe they are constipated.6 In this group of patients, constipation is likely to
be the result of a perceived difficulty with evacuation or
the presence of hard stools. Patients may experience
bloating and abdominal pain or discomfort, and they
may exhibit increased psychosocial distress6; some may
have increased rectal compliance, reduced rectal sensa-
tion, or both.86 Symptoms of constipation
typically respond to therapy with dietary
fiber alone or with the addition of an
osmotic laxative.87
Lack of a response to these therapies
may reflect a disturbance of evacuation or
transit that requires further management.
Defecatory disorders are most commonly
the result of dysfunction of the pelvic floor or
anal sphincter. Other terms used to describe
defecatory disorders include anismus; pelvicfloor dyssynergia; paradoxical pelvic-floor
contraction; obstructed constipation; functional rectosigmoid obstruction; the spastic
pelvic floor syndrome; and functional fecal
retention in childhood. Functional fecal
retention in children may result in secondary
encopresis88 as a result of leakage of liquid
stool around impacted stool, which can lead
to an initial misdiagnosis of diarrhea.
Prolonged avoidance of the pain associated
with either the passage of a large, hard stool or
an anal fissure or hemorrhoid may result in
defecatory disorders.89 Structural abnormalities, such as rectal intussusception, rectocele,
obstructing sigmoidocele, and excessive perineal descent, are less common causes of
defecatory disorders. Some patients with
defecatory disorders have a history of sexual
or physical abuse or an eating disorder.
Failure of the rectum to empty effectively
may be the result of an inability to coordinate the abdominal, rectoanal, and pelvicfloor muscles during defecation.5,90
These dysfunctions can be identified
clinically and with the use of defecography
as reduced descent of the perineum (less
than 1 cm) and a reduced change in the
anorectal angle (usually less than 15
degrees) during simulation of straining to
defecate (Table 2). Ignoring or suppressing
the urge to defecate may contribute to the
development of mild constipation91 before
the evacuation disorder becomes severe.
Slow-transit constipation occurs most
Table 1. Rome II Criteria for Constipation*
2 or more of the following for at least 12 weeks (not necessarily consecutive) in the
preceding 12 months:
• Straining during >25% of bowel movements
• Lumpy or hard stools for >25% of bowel movements
• Sensation of incomplete evacuation for >25% of bowel movements
• Sensation of anorectal blockage for >25% of bowel movements
• Manual maneuvers to facilitate >25% of bowel movements (eg, digital evacuation
or support of the pelvic floor)
• <3 bowel movements per week
• Loose stools not present, and insufficient criteria for IBS
Infants and Children
• Pebble-like, hard stools for a majority of bowel movements for at least 2 weeks
• Firm stools <2 times per week for at least 2 weeks
• No evidence of structural, endocrine, or metabolic disease
*Reprinted with permission from Thompson WG, Longstreth GF, Drossman DA, Heaton KW,
Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut.
1999;45:(suppl II):43-47.3
Table 2. Diagnostic Findings in Patients With Defecatory Disorders
• Prolonged straining to expel stool
• Unusual postures on the toilet to facilitate stool expulsion
• Support of the perineum, digitation of rectum, or posterior vaginal pressure to facilitate rectal emptying
• Inability to expel enema fluid
• Constipation after subtotal colectomy for constipation
Rectal examination (with patient in left lateral position)
• Inspection
• Anus pulled forward while the patient is bearing down
• Anal verge descends <1.0 cm or >3.5 cm (or beyond the ischial tuberosities) while
the patient is bearing down
• Perineum balloons down while the patient is bearing down, and rectal mucosa partially prolapses through anal canal
• Palpation
• High anal-sphincter tone at rest
• Anal-sphincter pressure during voluntary contraction is only slightly higher than tone
at rest
• Perineum and examining finger descend <1.0 cm or >3.5 cm while patient simulates straining during defecation
• Puborectalis muscle is tender on palpation through the rectal wall posteriorly, or
palpation produces pain
• Palpable mucosal prolapse during straining
• Defect in anterior wall of the rectum, suggestive of rectocele
Anorectal manometry and balloon expulsion (with patient in left lateral position)
• Average tone of anal sphincter at rest, >80 cm water (or >60 mm Hg)
• Average pressure of anal sphincter during contraction, >240 cm water (or >180
mm Hg)
• Failure to expel balloon
*Reprinted with permission from Lembo T, Camilleri M. Chronic constipation. N Engl J Med.
2003;349:1360-1368.20 Copyright © 2003. Massachusetts Medical Society. All rights reserved.
Vol. 5 (10B)
November 2005
Figure 3. Distribution of Interstitial Cells*
Slow transit constipation
Distribution of interstitial cells of Cajal in whole transverse mounts of the sigmoid colon in a normal-appearing disease control section of the sigmoid
colon (left) and the sigmoid colon of a patient with slow-transit constipation.
*Reprinted with permission from He et al.96
commonly92 in young women who have infrequent
bowel movements (1 or fewer per week). Often,
this condition begins in puberty. Associated symptoms are an infrequent urge to defecate, bloating,
and abdominal pain or discomfort. In patients with
a minimal delay in colonic transit, dietary and cultural factors contribute to symptoms. In these
patients, a high-fiber diet may increase stool
weight, decrease colon-transit time, and relieve
constipation. Patients with more severe slow-transit
constipation have a poor response to dietary
fiber87,92 and laxatives. Such patients have more
delayed emptying of the proximal colon15 and
fewer high-amplitude peristaltic contractions after
meals, which normally induce movement of content through the colon. Colonic inertia, a related
condition, is characterized by slow colonic transit
and the lack of an increase in motor activity after
meals or after the administration of bisacodyl,92
cholinergic agents, or anticholinesterases such as
Histopathologic studies in patients with slowtransit constipation have shown alterations in the
Advanced Studies in Medicine
number of myenteric plexus neurons expressing the excitatory neurotransmitter, substance P,94 abnormalities in
the inhibitory transmitters, vasoactive intestinal peptide,
and nitric oxide,95 and a reduction in the number of
interstitial cells of Cajal,96 which are thought to regulate
gastrointestinal motility (Figures 3 and 4).
Hirschsprung’s disease is an extreme form of slowtransit constipation with similar enteric neuropathologic
features. In Hirschsprung’s disease, ganglion cells in the
distal bowel are absent, a result of an arrest in the caudal
migration of neural-crest cells through the gut during
embryonic development; and the bowel narrows at the
area that lacks ganglion cells. Though most patients with
this disorder present in infancy or early childhood, some
patients with a relatively short segment of involved colon
do not show symptoms until later in life.97 Hirschsprung’s
disease is associated with mutations in the RET protooncogene or the gene for the endothelin-B receptor.98
The role of colonic absorption of fluids and electrolytes in the etiopathogenesis of constipation is unclear.
Sodium-hydrogen and sodium-potassium exchanges
occur in the proximal and distal colon under mineralo-
Figure 4. High Magnification of Interstitial Cells of Cajal in the
Circular Muscle of Human Sigmoid Colon*
High-magnification confocal microscopy of the interstitial cells of Cajal from human sigmoid
colon. A and C are single slices; B and D are reconstructions of 20 consecutive single slices.
A and B are from a healthy-appearing disease control colon; note multiple fine processes
and the network of interconnecting interstitial cells of Cajal. C and D are from a patient with
slow-transit constipation. Note the irregular markings and loss of fine processes (bar =
10 microns).
*Reprinted with permission from He et al.96
corticoid control; however, there appear to be no reports
of disturbances in these exchanges or the related aquaporins in common constipation disorders. On the other
hand, fluid and electrolyte handling in the colon is
extremely important in determining stool consistency.
The colon has a vast capacity to reabsorb water and electrolytes.99,100 Conversely, patients with constipation tend
to benefit from fiber, osmotic laxatives, stool softeners,
and stimulant laxatives (eg, bisacodyl). In disease states
such as carcinoid diarrhea, small intestinal secretion may
contribute to the accelerated emptying of the proximal
colon.40 The induction of small intestinal secretion via
osmotic or pharmacologic agents appears to result in
acceleration of small bowel or colonic transit, such as with
lactulose101 or lubiprostone, a novel chloride channel activator.102 This combination of secretion and accelerated
transit is associated with relief of chronic constipation.103
IBS and constipation are commonly encountered
clinical disorders; their pathophysiology and mechanisms are more clearly understood, and novel treatments based on this greater understanding will lead to
optimized treatment.
1. Drossman DA, Corazziari E, Talley NJ, Thompson WG,
Whitehead WE, eds. The Functional Gastrointestinal
Disorders: Diagnosis, Pathophysiology and Treatment: A
Multinational Consensus. McLean, Va: Degnon
Associates; 2000.
2. Drossman DA. The functional gastrointestinal disorders and
the Rome II process. Gut. 1999;45(suppl II):1-5.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW,
Irvine EJ, Muller-Lissner SA. Functional bowel disorders and
functional abdominal pain. Gut. 1999;4(suppl II):43-47.
4. Manning AP, Thompson WG, Heaton KW, Morris AF.
Towards positive diagnosis of the irritable bowel. BMJ.
5. Camilleri M, Thompson WG, Fleshman JW, Pemberton JH.
Clinical management of intractable constipation. Ann Intern
Med. 1994;121:520-528.
6. Ashraf W, Park F, Lof J, Quigley EM. An examination of the
reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol. 1996;91:26-32.
7. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon
FE, Hughes AO. Defecation frequency and timing, and
stool form in the general population: a prospective study.
Gut. 1992;33:818-824.
8. Drossman DA, Camilleri M, Mayer EA, Whitehead WE.
AGA technical review on irritable bowel syndrome.
Gastroenterology. 2002;123:2108-2131.
9. Spiller RC. Infection, immune function, and functional gut
disorders. Clin Gastroenterol Hepatol. 2004;2:445-455.
10. Camilleri M. Motor function in irritable bowel syndrome.
Can J Gastroenterol. 1999;13(suppl A):8A-11A.
11. Choi M-G, Camilleri M, O’Brien MD, Kammer PP, Hanson
RB. A pilot study of motility and tone of the left colon in
diarrhea due to functional disorders and dysautonomia.
Am J Gastroenterol. 1997;92:297-302.
12. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic
motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J
Gastroenterol. 2001;96:1499-1506.
13. O’Brien MD, Camilleri M, von der Ohe MR, et al. Motility
and tone of the left colon in constipation: a role in clinical
practice? Am J Gastroenterol. 1996;91:2532-2538.
14. Cann PA, Read NW, Brown C, Hobson N, Holdsworth
CD. Irritable bowel syndrome: relationship of disorders in
the transit of a single solid meal to symptom patterns. Gut.
15. Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation.
Gastroenterology. 1991;101:107-115.
16. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman
NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome.
Gastroenterology. 1992;102:102-108.
17. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome.
Gut. 2001;48:14-19.
18. Hasler WL. Air apparent: studies of gas and bloating in
IBS. Gastroenterology. 2002;122:576-577.
19. Lanfranchi GA, Bazzocchi G, Brignola C, Campieri M,
Labo G. Different patterns of intestinal transit time and
anorectal motility in painful and painless chronic constipation. Gut. 1984;25:1352-1357.
20. Lembo A, Camilleri M. Chronic constipation. N Engl J
Med. 2003;349:1360-1368.
21. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel
syndrome and dyspepsia in the general population: overlap
and lack of stability over time. Gastroenterology.
22. Locke GR III, Murray JA, Zinsmeister AR, Melton LJ III, Talley
NJ. Celiac disease serology in irritable bowel syndrome
and dyspepsia: a population-based, case-control study.
Mayo Clin Proc. 2004;79:476-482.
23. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA.
Altered rectal perception is a biological marker of patients
with irritable bowel syndrome. Gastroenterology.
24. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity,
specificity, and predictive values of pain sensory thresholds.
Gastroenterology. 2002;122:1771-1777.
25. Hobday DI, Hobson A, Furlong PL, Thompson DG, Aziz Q.
Comparison of cortical potentials evoked by mechanical
and electrical stimulation of the rectum. Neurogastroenterol
Motil. 2000;12:547-554.
26. Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee
AA. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome.
Neurogastroenterol Motil. 2002;14:241-247.
27. Bouin M, Lupien F, Riberdy M, Boivin M, Plourde V, Poitras
P. Intolerance to visceral distension in functional dyspepsia
or irritable bowel syndrome: an organ specific defect or a
pan intestinal dysregulation? Neurogastroenterol Motil.
28. Kwan CL, Davis KD, Mikula K, Diamant NE. Abnormal rectal motor physiology in patients with irritable bowel syn-
Vol. 5 (10B)
November 2005
drome. Neurogastroenterol Motil. 2004;16:251-263.
29. Mertz H, Morgan V, Tanner G, et al. Regional cerebral
activation in irritable bowel syndrome and control subjects
with painful and nonpainful rectal distention.
Gastroenterology. 2000;118:842-848.
30. Hamaguchi T, Kano M, Rikimaru H, et al. Brain activity during distention of the descending colon in humans.
Neurogastroenterol Motil. 2004;16:299-309.
31. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal
mucosal enteroendocrine cells, T lymphocytes, and
increased gut permeability following acute Campylobacter
enteritis and in post-dysenteric irritable bowel syndrome.
Gut. 2000;47:804-811.
32. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and
depression in postinfectious IBS. Gastroenterology.
33. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable
bowel syndrome. Am J Gastroenterol. 2003;98:1578-1583.
34. Wang LH, Fang XC, Pan GZ, Rodriguez E. Bacillary dysentery as a causative factor of irritable bowel syndrome and
its pathogenesis. Gut. 2004;53:1096-1101.
35. Chadwick VS, Chen W, Shu D, et al. Activation of the
mucosal immune system in irritable bowel syndrome.
Gastroenterology. 2002;122:1778-1783.
36. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal
ileal mucosal mast cells in irritable bowel syndrome. Dig
Dis Sci. 1993;38:1590-1595.
37. O’Sullivan M, Clayton N, Breslin NP, et al. Increased mast
cells in the irritable bowel syndrome. Neurogastroenterol
Motil. 2000;12:449-457.
38. Barbara G, Stanghellini V, De Giorgio R, et al. Activated
mast cells in proximity to colonic nerves correlate with
abdominal pain in irritable bowel syndrome.
Gastroenterology. 2004;126:693-702.
39. Dunlop SP, Jenkins D, Neal KR, et al. Randomized, doubleblind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther.
40. von der Ohe M, Camilleri M, Kvols LK, Thomforde GM.
Motor dysfunction of the small bowel and colon in patients
with the carcinoid syndrome and diarrhea. N Engl J Med.
41. von der Ohe MR, Camilleri M, Kvols LK. A 5HT3 antagonist
corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology. 1994;106:1184-1189.
42. Saslow SB, Scolapio JS, Camilleri M, et al. Medium-term
effects of a new 5HT3 antagonist, alosetron, in patients
with carcinoid diarrhea. Gut. 1998;42:628-634.
43. Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma
5-hydroxytryptamine in diarrhoea predominant irritable
bowel syndrome: a pilot study. Gut. 1998;42:42-46.
44. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ,
Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable
bowel syndrome. Gut. 2003;52:663-670.
45. Ragnarsson G, Bodemar G. Pain is temporally related to
eating but not to defaecation in the irritable bowel syndrome (IBS). Patients’ description of diarrhoea, constipation
and symptom variation during a prospective 6 week study.
Eur J Gastroenterol Hepatol. 1998;10:415-421.
46. Cremonini F, Camilleri M. Of actors, bolting horses, and
drops in oceans! Gut. 2003;52:619-621.
Advanced Studies in Medicine
47. Coates MD, Mahoney CR, Linden DR, et al. Molecular
defects in mucosal serotonin content and decreased serotonin
reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126:1657-1664.
48. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant IBS. Gastroenterology. 2002;123:425-432.
49. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil.
50. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Review:
tegaserod for the treatment of irritable bowel syndrome.
Cochrane Database Syst Rev. 2004;1:CD003960.
51. Kalantar JS, Locke GR III, Zinsmeister AR, Beighley CM,
Talley NJ. Familial aggregation of irritable bowel syndrome:
a prospective study. Gut. 2003;52:1703-1707.
52. Locke GR III, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ III.
Familial association in adults with functional gastrointestinal
disorders. Mayo Clin Proc. 2000;75:907-912.
53. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews
G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93:1311-1317.
54. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ,
Corey LA. Irritable bowel syndrome in twins: heredity and
social learning both contribute to etiology.
Gastroenterology. 2001;121:799-804.
55. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill
NJ. Genetic influences in irritable bowel syndrome: a twin
study. Am J Gastroenterol. 2005;100:1340-1344.
56. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ,
Hutchinson IV. Interleukin 10 genotypes in irritable bowel
syndrome: evidence for an inflammatory component? Gut.
57. Holtmann G, Siffert W, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology. 2004;126:971-979.
58. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene
regulatory region. Science. 1996;274:1527-1531.
59. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha-2A adrenoceptor and serotonin-transporter polymorphisms associated with constipation and somatic
symptoms in functional gastrointestinal disorders. Gut.
60. Camilleri M. Is there a SERT-ain association with IBS? Gut.
61. Yeo A, Boyd P, Lumsden S, et al. Association between a
functional polymorphism in the serotonin transporter gene
and diarrhoea predominant irritable bowel syndrome in
women. Gut. 2004;53:1452-1458.
62. Lee DY, Park H, Kim WH, Lee SI, Seo YJ, Choi YC.
Serotonin transporter gene polymorphism in healthy adults
and patients with irritable bowel syndrome. Korean J
Gastroenterol. 2004;43:18-22.
63. Pata C, Erdal ME, Derici E, et al. Serotonin transporter
gene polymorphism in irritable bowel syndrome. Am J
Gastroenterol. 2002;97:1780-1784.
64. Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid
malabsorption-a review of clinical presentation, diagnosis, and
response to treatment. Gut. 1991;32:1004-1006.
65. Oddsson E, Rask-Madsen J, Krag E. A secretory epithelium
of the small intestine with increased sensitivity to bile acids
in irritable bowel syndrome associated with diarrhoea.
Scand J Gastroenterol. 1978;13:408-416.
66. Sciarretta G, Fagioli G, Furno A, et al. 75Se HCAT test in
the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut.
67. Spiller RC, Brown ML, Phillips SF. Decreased fluid tolerance, accelerated transit, and abnormal motility of the
human colon induced by oleic acid. Gastroenterology.
68. Kamath PS, Phillips SF, O’Connor MK, Brown ML,
Zinsmeister AR. Colonic capacitance and transit in man:
modulation by luminal contents and drugs. Gut.
69. Kamath PS, Phillips SF, Zinsmeister AR. Short-chain fatty
acids stimulate ileal motility in humans. Gastroenterology.
70. Kruis W, Haddad A, Phillips SF. Chenodeoxycholic and
ursodeoxycholic acids alter motility and fluid transit in the
canine ileum. Digestion. 1986;34:185-195.
71. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ,
Cook IJ. The proximal colonic motor response to rectal
mechanical and chemical stimulation. Am J Physiol.
72. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B.
Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol.
73. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
Aliment Pharmacol Ther. 2003;17:895-904.
74. Kim HJ, Vazquez Roque M, Camilleri M, et al. A randomized, controlled trial of a probiotic combination, VSL#3, in
irritable bowel syndrome with bloating. Neurogastroenterol
Motil. In press.
75. Quigley E, O’Mahony L, McCarthy J, et al. Probiotics for
the irritable bowel syndrome (IBS): a randomized, doubleblind, placebo-controlled comparison of Lactobacillus and
Bifidobacterium species. Gastroenterology.
76. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose
breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebocontrolled study. Am J Gastroenterol. 2003;98:412-419.
77. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology
of constipation (EPOC) study in the United States: relation of
clinical subtypes to sociodemographic features. Am J
Gastroenterol. 1999;94:3530-3540.
78. Sonnenberg A, Koch TR. Physician visits in the United States
for constipation: 1958 to 1986. Dig Dis Sci.
79. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An
epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care
seeking. Am J Gastroenterol. 2001;96:3130-3137.
80. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld
P, Talley NJ. Systematic review on the management of
chronic constipation in North America. Am J Gastroenterol.
2005;100(suppl 1):S5-S21.
81. Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology
of chronic constipation. J Clin Gastroenterol.
82. Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP,
White LR. A longitudinal survey of self-reported bowel habits in
the United States. Dig Dis Sci. 1989;34:1153-1162.
83. Sandler RS, Drossman DA. Bowel habits in young adults not
seeking health care. Dig Dis Sci. 1987;32:841-845.
84. Koch A, Voderholzer WA, Klauser AG, Muller-Lissner S.
Symptoms in chronic constipation. Dis Colon Rectum.
85. Nyam DC, Pemberton JH, Ilstrup DM, Rath DM. Long-term
results of surgery for chronic constipation. Dis Colon
Rectum. 1997;40:273-279. Erratum in Dis Colon Rectum.
86. Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am J Gastroenterol. 1999;94:609-615.
87. Voderholzer WA, Schatke W, Muhldorfer BE, Klauser AG,
Birkner B, Muller-Lissner SA. Clinical response to dietary
fiber treatment of chronic constipation. Am J Gastroenterol.
88. Doig CM. ABC of colorectal diseases: paediatric problems. BMJ. 1992;305:462-464.
89. Loening-Baucke V. Encopresis and soiling. Pediatr Clin
North Am. 1996;43:279-298.
90. Rao SS, Welcher KD, Leistikow JS. Obstructive defecation:
a failure of rectoanal coordination. Am J Gastroenterol.
91. Klauser AG, Voderholzer WA, Heinrich CA, Schindlbeck
NE, Muller-Lissner SA. Behavioral modification of colonic
function: can constipation be learned? Dig Dis Sci.
92. Preston DM, Lennard-Jones JE. Severe chronic constipation
of young women: ‘idiopathic slow transit constipation.’ Gut.
93. Bassotti G, Chiarioni G, Imbimbo BP, et al. Impaired
colonic motor response to cholinergic stimulation in patients
with severe chronic idiopathic (slow transit type) constipation. Dig Dis Sci. 1993;38:1040-1045.
94. Tzavella K, Riepl RL, Klauser AG, Voderholzer WA,
Schindlbeck NE, Muller-Lissner SA. Decreased substance P
levels in rectal biopsies from patients with slow transit constipation. Eur J Gastroenterol Hepatol. 1996;8:1207-1211.
95. Cortesini C, Cianchi F, Infantino A, Lise M. Nitric oxide
synthase and VIP distribution in enteric nervous system in
idiopathic chronic constipation. Dig Dis Sci.
96. He CL, Burgart L, Wang L, et al. Decreased interstitial cell
of Cajal volume in patients with slow-transit constipation.
Gastroenterology. 2000;118:14-21.
97. Barnes PR, Lennard-Jones JE, Hawley PR, Todd IP.
Hirschsprung’s disease and idiopathic megacolon in adults
and adolescents. Gut. 1986;27:534-541.
98. Edery P, Pelet A, Mulligan LM, et al. Long segment and
short segment familial Hirschsprung’s disease: variable clinical expression at the RET locus. J Med Genet.
99. Debongnie JC, Phillips SF. Capacity of the human colon to
absorb fluid. Gastroenterology. 1978;74:698-703.
100. Hammer J, Phillips SF. Fluid loading of the human colon:
effects on segmental transit and stool composition.
Gastroenterology. 1993;105:988-998.
101. Barrow L, Steed KP, Spiller RC, et al. Scintigraphic
demonstration of lactulose-induced accelerated proximal
colon transit. Gastroenterology. 1992;103:1167-1173.
102. Camilleri M, Bharucha AE, Panas RM, et al. Effect of a
chloride channel activator, lubiprostone, on gastrointestinal
transit, gastric sensory and motor functions in humans
[abstract]. Neurogastroenterol Motil. In press.
103. Johanson JF, Gargano MA, Holland PC, Patchen ML,
Ueno R. Phase III efficacy and safety of RU-0211, a novel
chloride channel activator, for the treatment of constipation. Gastroenterology. 2003;124:A48.
Vol. 5 (10B)
November 2005